K.J. Harrison & Partners’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

K.J. Harrison & Partners’s Portfolio BCTXW Stock Details BCTXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-68,885	Closed	-$172K	–	128
2023 Q2	$172K	Sell	68,885 -101,865	-60%	-$281K	0.03%	201
2023 Q1	$505K	Sell	170,750 -37,626	-18%	-$108K	0.1%	157
2022 Q4	$581K	Sell	208,376 -4,340	-2%	-$10.1K	0.11%	152
2022 Q3	$610K	Buy	212,716 +31,440	+17%	+$93.9K	0.22%	99
2022 Q2	$472K	Buy	181,276 +21,219	+13%	+$67.7K	0.13%	130
2022 Q1	$832K	Buy	160,057 +44,910	+39%	+$179K	0.13%	137
2021 Q4	$541K	Sell	115,147 -1,299	-1%	-$6.13K	0.08%	189
2021 Q3	$556K	Buy	+116,446	New	+$286K	0.08%	196
2021 Q2	–	Sell	-10,000	Closed	-$11K	–	361
2021 Q1	$11K	Buy	+10,000	New	+$9.79K	﹤0.01%	317

Other funds holding BCTXW

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

K.J. Harrison & Partners's BCTXW Position: Q3 2023 in Review

K.J. Harrison & Partners sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q3 2023, closing a stake of 68,885 shares — an estimated $172K sold.

K.J. Harrison & Partners first reported a position in BCTXW in Q1 2021 and held it in 9 quarters. The position peaked at $832K in Q1 2022. 4 funds tracked by Wall St. Rank hold BCTXW as of Q3 2023.

K.J. Harrison & Partners reported no remaining BriaCell Therapeutics Corp Warrant position as of Q3 2023 after selling out during the quarter.
K.J. Harrison & Partners sold 68,885 BriaCell Therapeutics Corp Warrant shares in Q3 2023, an estimated $172K.
K.J. Harrison & Partners first reported a position in BriaCell Therapeutics Corp Warrant in Q1 2021 and held it in 9 quarters.
K.J. Harrison & Partners's BriaCell Therapeutics Corp Warrant position peaked at $832K in Q1 2022.
4 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q3 2023.

Based on K.J. Harrison & Partners's 13F filing for Q3 2023, filed 31 Oct 2023.